Eli Lilly Halts Alzheimer's Drug Trial
INDIANAPOLIS (TheStreet) -- Eli Lilly (LLY) was forced to halt development of an experimental Alzheimer's disease drug after an early look at results from two late-stage clinical trials determined the drug to be ineffective.
Lilly shares fell 2% to $34.75 in Tuesday's pre-market trading on news of the setback for the Alzheimer's drug semagacestat, one of two drugs being in the company's pipeline that are in late-stage studies against the neuro-degenerative disease.
The failure of semagacestat will also heighten concerns about Lilly's future growth given the looming loss of patent protection through 2014 on drugs that presently account for 60% of the company's revenue.
Tuesday, Lilly said it would take a charge of 3-4 cents a share in the third quarter to account for the halting of the semagacestat clinical trials. The company reiterated 2010 guidance of $4.44 to $4.59 a share on a reported basis.The two phase III clinical trials of semagacestat enrolled more than 2,600 patients with mild to moderate Alzheimer's, randomizing them to treatment with semagacestat or a placebo. An interim analysis of the studies found that semagacestat-treated patients were performing worse on tests of cognition and ability to complete daily living tasks compared to patients treated with a placebo. In addition, semagacestat patients were at a higher risk for developing skin cancer. Lilly said Tuesday that phase III trials involving the company's other late-stage Alzheimer's drug solanezumab are continuing. Both semagacestat and solanezumab are designed to reduce the levels of amyloid beta plaques, protein substances that attach to and destroy neurons in the brain. Amyloid beta is thought to one of the causes of Alzheimer's. Semagacestat works by inhibiting an enzyme, gamma secretase, which the body uses to form amyloid beta plaques. Earlier this year, Pfizer (PFE) and Medivation (MDVN) said a phase III study of their Alzheimer's drug Dimebon also failed, although additional clinical trials of that drug continue. -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV